Compare Merck & Co., Inc. (MRK) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Merck & Co., Inc. trades at $148 (market cap $363.98B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $44.53. The key difference: Merck & Co., Inc. pays a 2.3% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| MRK | VNQI | |
|---|---|---|
Market Cap | $363.98B | — |
Sector | Health | — |
52-Week High | $156.43 | $50.76 |
52-Week Low | $77.60 | $43.26 |
Enterprise Value | $410.75B | — |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
VNQI, the Vanguard Global ex-U.S. Real Estate ETF, trades at $44.95, down 0.71% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF focuses on international real estate across over 30 countries, offering a higher dividend yield than many peers but has shown lower total returns recently. Recent news highlights its price crossing below the 50-day moving average and comparisons with other real estate ETFs.
The outlook for VNQI is cautious due to bearish technical trends and underperformance versus U.S.-focused real estate ETFs. Opportunities include diversification benefits and attractive dividend yield, but risks involve global economic sensitivity and currency fluctuations. Investors should weigh international exposure against potential volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
